Skip to main
OMER

Omeros (OMER) Stock Forecast & Price Target

Omeros (OMER) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Omeros is a promising investment opportunity with a positive long-term outlook due to its innovative pipeline targeting large-market and orphan indications, with a strong focus on complement-mediated diseases, cancers, and addictive or compulsive disorders. With ongoing clinical development programs for narsoplimab and OMS1029, as well as potential approval for OMS527 in the near future, the company has multiple paths for growth and potential revenue generation. Furthermore, the company's current partnership with Novo Nordisk, as well as its strong commercialization strategy and balanced risk profile, further support a positive outlook on Omeros' stock as it continues to drive revenue, margin expansion, and cash flow growth.

Bears say

Omeros is a biotechnology company with a negative outlook due to potential limitations in enrollment of the sickest patients in its current clinical trials, as well as high barriers to adoption and growth for its products in the competitive transplant market. Additionally, while the company expects YARTEMLEA to become the standard of care for TA-TMA, there are uncertainties surrounding reimbursement and competition for indications involving lectin pathway activation. As such, the company's financial success and stock valuation may be hindered in the long term.

Omeros (OMER) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Omeros and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Omeros (OMER) Forecast

Analysts have given Omeros (OMER) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Omeros (OMER) has a Strong Buy consensus rating as of Aug 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Omeros (OMER)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.